Suzetrigine is an orally available pain signal inhibitor that selectively targets the NaV1.8 voltage-gated sodium channel, a genetically validated pain target found on peripheral neurons. NaV1.8 is ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, today we look at ...
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Fintel on MSN7h
Wells Fargo Downgrades Vertex Pharmaceuticals (VRTX)Fintel reports that on January 30, 2025, Wells Fargo downgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from ...
Wells Fargo analyst Mohit Bansal downgraded Vertex Pharmaceuticals (VRTX) to Equal Weight from Overweight with an unchanged price target of ...
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company with a market capitalization of $113.7 billion, is navigating a critical juncture as it seeks to expand its therapeutic reach and ...
If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback